JP2017535794A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535794A5
JP2017535794A5 JP2017543287A JP2017543287A JP2017535794A5 JP 2017535794 A5 JP2017535794 A5 JP 2017535794A5 JP 2017543287 A JP2017543287 A JP 2017543287A JP 2017543287 A JP2017543287 A JP 2017543287A JP 2017535794 A5 JP2017535794 A5 JP 2017535794A5
Authority
JP
Japan
Prior art keywords
seq
pif
cells
analog
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017543287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535794A (ja
Filing date
Publication date
Priority claimed from PCT/US2015/050532 external-priority patent/WO2016044493A1/en
Application filed filed Critical
Priority claimed from PCT/US2015/058877 external-priority patent/WO2016073513A1/en
Publication of JP2017535794A publication Critical patent/JP2017535794A/ja
Publication of JP2017535794A5 publication Critical patent/JP2017535794A5/ja
Pending legal-status Critical Current

Links

JP2017543287A 2014-11-03 2015-11-03 免疫調節不全についてのマーカーとしてのpif結合 Pending JP2017535794A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462074384P 2014-11-03 2014-11-03
US62/074,384 2014-11-03
US201562113298P 2015-02-06 2015-02-06
US62/113,298 2015-02-06
US201562211660P 2015-08-28 2015-08-28
US62/211,660 2015-08-28
PCT/US2015/050532 WO2016044493A1 (en) 2014-09-16 2015-09-16 Compositions and methods for treating acute radiation syndrome
USPCT/US2015/050532 2015-09-16
PCT/US2015/058877 WO2016073513A1 (en) 2014-11-03 2015-11-03 Pif binding as a marker for immune dysregulation

Publications (2)

Publication Number Publication Date
JP2017535794A JP2017535794A (ja) 2017-11-30
JP2017535794A5 true JP2017535794A5 (https=) 2018-12-13

Family

ID=55909715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543287A Pending JP2017535794A (ja) 2014-11-03 2015-11-03 免疫調節不全についてのマーカーとしてのpif結合

Country Status (7)

Country Link
US (1) US20180318386A1 (https=)
EP (1) EP3215847A4 (https=)
JP (1) JP2017535794A (https=)
AU (2) AU2015343202A1 (https=)
CA (1) CA2965973A1 (https=)
IL (1) IL251667A0 (https=)
WO (1) WO2016073513A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017039751A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2017079430A1 (en) * 2015-11-03 2017-05-11 Bioincept, Llc Peptides and methods of treating endometriosis using the same
EP3341006A4 (en) 2015-08-28 2019-03-13 BioIncept LLC COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
US20230190867A1 (en) * 2018-02-22 2023-06-22 Bioincept, Llc Methods of treating nash and compositions therefore
CN113640092A (zh) * 2020-04-23 2021-11-12 复旦大学 石蜡包埋组织样本的处理方法以及其质谱检测方法
US20230400471A1 (en) * 2020-10-15 2023-12-14 Bioincept, Llc Systems, compositions and methods of determining viability of embryos using the same
WO2025078961A1 (en) * 2023-10-13 2025-04-17 Gufic Biosciences Limited Composition and method for treatment of endometriosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
ATE374370T1 (de) * 1999-01-25 2007-10-15 Siemens Medical Solutions Diag Verfahren zur diagnose von endometriose
US8222211B2 (en) * 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
US7273708B2 (en) * 2001-07-02 2007-09-25 Bioincept, Llc Assays for preimplantation factor and preimplantation factor peptides
US7723289B2 (en) * 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
EP2479277B1 (en) * 2004-07-22 2015-09-02 Five Prime Therapeutics, Inc. Use of MGD-CSF in a method of treatment of Alzheimer's disease.
WO2006087722A1 (en) * 2005-02-17 2006-08-24 Hadasit Medical Research Services And Development Ltd. Bisphosphonates for treating endometriosis
US20070136003A1 (en) * 2005-12-08 2007-06-14 Electronics And Telecommunications Research Institute Method and system of verifying protein-protein interaction using protein homology relationship
US9737585B2 (en) * 2011-03-02 2017-08-22 Bioincept, Llc Compositions and methods for treatment of intracellular damage and bacterial infection

Similar Documents

Publication Publication Date Title
JP2017535794A5 (https=)
JP7430136B2 (ja) 疲弊したt細胞に関連する疾患を治療するための方法および組成物
US8647822B2 (en) Determining whether a test compound modulates PD-1 activity in activated immune cells using gene expression profiles
Roedder et al. Biomarkers in solid organ transplantation: establishing personalized transplantation medicine
US20220373538A1 (en) Composition for determination of cell-mediated immune responsiveness
TW201243328A (en) Diagnostic and therapeutic uses for B cell maturation antigen
JP2005510251A (ja) サルコイドーシスの評価法と予後判定法
WO2016185182A1 (en) Detection of t cell exhaustion or lack of t cell costimulation and uses thereof
Mensink et al. Tregs from human blood differentiate into nonlymphoid tissue–resident effector cells upon TNFR2 costimulation
JP2021528965A (ja) 多発性硬化症における免疫優性タンパク質および断片
US20210052593A1 (en) Compositions and Methods for the Treatment of Macrophage Activation Syndrome
Schreibing et al. Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell epitope mapping
EP1963551A1 (en) Markers for memory t cells and uses thereof
US11567065B2 (en) Measuring frequency of pathogen-specific T cells in peripheral blood
WO2021044056A1 (en) Method for determining the effectiveness of a nanoparticle-based therapy
Heikkilä et al. Expanded CD4+ effector/memory T cell subset in APECED produces predominantly interferon gamma
WO2013086304A1 (en) Methods and compositions for diagnosing neurodegenerative disease
Samani et al. Alteration in CD8+ T cell subsets in enterovirus-infected patients: an alarming factor for type 1 diabetes mellitus
KR20170089334A (ko) 말초혈액 내의 hla-dr+ t 세포의 비율을 이용하여 신장이식환자에서 미세혈관 염증 또는 항체 매개성 거부반응을 진단하는 방법
JP2014163769A (ja) 患者検体を用いたhtlv−1キャリア、成人t細胞白血病の発癌過程進行度又は悪性度の評価法
CN102918396B (zh) 利用人类白血球抗原(hla)筛检预测药物不良反应的方法
Ravishankar et al. T-cells specific for KSHV and HIV migrate to Kaposi sarcoma tumors and persist over time
CN116802320A (zh) 使用细环病毒(ttv)作为确定t淋巴细胞增殖能力的标志
US20200319164A1 (en) Methods for detecting, assessing severity and treating multiple sclerosis
Mead et al. Integrated, high-dimensional analysis of CD4 T cell epitope specificities and phenotypes reveals unexpected diversity in the response to Mycobacterium tuberculosis